Galecto Corp - נכסים נקיים למניה בודדת GLTO

Galecto, Inc. (GLTO) drug development for cancer and fibrosis remains independent of macroeconomic trends, as confirmed by the key book value metric on GURU.Markets, where the current level is approximately 4.98. High scaling potential through contract synthesis enables the company to capture global markets. The business is currently focusing on clinical trials of innovative galectin inhibitors to combat tissue scarring.

This indicator determines the intrinsic value of the business by measuring the residual capital per share after the full settlement of all liabilities. By analyzing the trend of the book value per share, an investor assesses the actual asset backing of Galecto, Inc. (GLTO), which is critical during cost optimization and while awaiting results for the GB1211 drug for liver cancer therapy.